Tag: minimal residual disease

Phase III trial shows survival benefit for early multiple myeloma

Minimal Residual Disease negativity after Autologous Hematopoietic Cell Transplantation with lenalidomide maintenance predicts better long-term outcomes in myeloma

byVanessa Giulianoand1 others

May 13, 2024

1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide maintenance, and at one-year post Auto-HCT (AutoHCT) predicts increased ...

#VisualAbstract: Chronic Lymphocytic Leukemia (CLL) therapy with Ibrutinib and Venetoclax guided by measurable residual disease improves progression-free survival

byMinjee Kim

January 31, 2024

#VisualAbstract: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia

byKathleen Lau

March 24, 2022

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

byKathleen Lau

February 3, 2022

#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma

byKathleen Lau

July 23, 2021

#VisualAbstract Changes in minimal residual disease status is associated with risk of disease progression in patients with multiple myeloma

byKathleen Lau

June 17, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result